Application

This monoclonal is useful in studies of complement and homologous restriction of complement action of the properties of GPI linked proteins and in the characterisation of cells from patients with PNH.

SUGGESTED USAGE DILUTION

1. Flow cytometry and indirect immunofluorescence 1:25

Dilute with isotonic buffer. Use 50 µl of the appropriate dilution per 1x10E6 cells in 100 µl buffer.

Detect CD59 using this Anti-CD59 Antibody, clone 2/24 validated for use in FC & IF.

Research Sub CategoryImmunoglobulins & Immunology

Research CategoryInflammation & Immunology

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

General description

BIOCHEMISTRY:

p I = 6.1

Immunogen

Human erythrocytes

Legal Information

CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany

Other Notes

Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.

Physical form

Purified immunoglobulin. The antibody is supplied in phosphate buffered saline, pH 7.4, containing 0.2% bovine serum albumin and 0.1% sodium azide. The characteristics of each lot are tested by electrophoresis and flow cytometry.

Format: Purified

Specificity

This antibody binds to a 17-25kD glycoprotein (Fletcher et al., 1990a,b) which is distributed on human cells and has a glycosyl-phosphatidylinositol (GPI) linkage to the plasma membrane(Hadam, 1989). It is identical to other CD59 monoclonals, MEM-43 and YTH 53.1, defined at the 4th International Conference on Human Leucocyte Differentiation Antigens(Davies et al., 1989; Stefanova et al., 1989). CD59 is an inhibitor of attack by autologous complement(Ojcius et al., 1990) possibly by limiting incorporation of C9 into the membrane complex(Rollins & Sims, 1990; Meri et al., 1990). GPI linked proteins such as CD59 are deficient on cells from patients with the acquired clonal disorder paroxysmal nocturnal haemoglobulinuria (PNH) in which the erythrocytes are susceptible to lysis by complement and leading to anemia(Rosse, 1990). Evidence suggests that CD59 may be the most important complement regulatory protein missing in PNH(Fletcher et al., 1990; Yamashina et al., 1990).

Cell reactivity (Fletcher et al., 1990a,b; Hadam, 1989):

The antibody reacts with all leucocytes, platelets, fibroblasts, erythrocytes and most cell lines. It is negative on U937 and Daudi cell lines. It is reduced on affected cells from patients with PNH with a distribution reflecting the clonal nature of the disease.

Storage and Stability

Store at 2 to 8°C, for up to 6 months. For prolonged periods, store below -20°C in undiluted aliquots. AVOID REPEATED FREEZE/THAW CYCLES.

WARNING: The monoclonal reagent solution contains 0.1% sodium azide as a preservative. Due to potential hazards arising from the build up of this material in pipes, spent reagent should be disposed of with liberal volumes of water.